and 2002. 3 Similarly, over a 13 year period,researchers in Quebec observed that mortality within 30 days of C. difficile diagnosis increased from 4.7% in 1991 to 13.8% in 2003 (p < 0.001). 4 In Pennsylvania alone,hospitalizations associated with C. difficiie increased by 298% between 1995 and 2005; additionally in 2005,patients with C. dijficile werehospitalized 2.5 times longer, charged morethan twiceas much,and were 4 times more likely to die," The increased morbidity and mortality is believed to be the result of an increased prevalence of a strain termed BIINAP1 , which currently accounts for 51% of C. difficiie infections, compared withonly 17% of historical isolates.
Since March 2003, BUNAP1 has been responsible for epidemics in the US, Canada, and throughout Europe.Its extreme virulence is blamedon 3 factors that differentiate it from previous strains. First, BIINAPI produces 3 toxins, instead of just 2. Additionally, BIINAPI containsa deletion in the tcdC gene, allowing BIINAPI to produce 16-23 times moretoxins A and B than previous strainsP and this strain is resistant to fluoroquinolone antibiotics. Independent risk factors for C. difficile diarrhea attributed to BIINAPI include use of fluoroquinolones, cephalosporins, and protonpump inhibitors''; therefore,judicious useof these medications is warranted. Greater emphasis on rapid restoration of normal flora may reduce the morbidity and mortalityassociatedwith this strain.
Difficult to Eradicate
As mentioned in Segarra-Newnham's" accompanying article, even historical strains of C. difficile are difficult to eradicate-roughly 20% of patients relapse within a short time of treatment; those with more than 2 relapses have a 50-65% chanceof additional relapses. It is estimatedthat 3 million Americans sufferfrom chronic,persistent C. difficile diarrhea and cannotstop takingvancomycin withoutexperiencinga relapse," Physicians at Harvard University havedetermined that a focal immunedeficiency may be responsible for chronic,relapsing C. difficile infections, as this subsetof affected patients fail to make antibodies against the organism and/or its toxins," This finding is noteworthy, as neither metronidazole nor vancomycin,the antibiotics usually prescribed to treatC. difficile diarrhea, are bactericidal against C. difficile spores. At best,these antibiotics eliminate vegetative forms of the disease,allowing the host immunesystemtime to mounta response to the bacterium.
No known antibiotics are capable of eliminating sporulating forms of C. difficile; thus, C. difficile spores lie dormant in the presence of metronidazole or vancomyin, but may germinate once the antimicrobial course of therapy has been completed, unless adequate amounts of healthy flora are present to keep the opportunistic organism from becoming pathogenic once again. As the spectrum of metronidazole's activity includes gut anaerobes and vancomycin covers gram-positiveorganisms,these antibiotics can actually suppressrestorationof normal gastrointestinal flora. This situation, in which metronidazole or vancomycin are needed to suppress C. difficile symptoms, but simultaneously hinder re-acquisition of normal gastrointestinal flora, makes clearing the organism impossible for individuals who fail to mount their own immune response against the microbe,"
For individuals affected by multiple relapses, treatment options are limited. Intravenous infusionsof immunoglobulin G have been used with some successJ' but this therapy is not without difficulties,including high cost, the need for repeated infusionsat 4 week intervals,and the potential for anaphylactic reactions or kidney failure. On the other hand, probiotics offer the potential of a noninvasive alternative. In addition, probiotic treatment for relapses can be substantiallymore cost-effective than traditional therapies. Nosocomial-acquired C. difficile relapses are estimated to cost more than $113 627 per person," with C. difficile infections costing the US healthcare system more than $1.1 billion annually." By way of cost comparison, 10 days' worth of vancomyin may cost $790-3152 (depending on dosage), compared with $50-100 for most probioticproducts. Some physicianshave even used the ultimateprobiot-ic approach-fecal transplants-in which feces obtained from healthy donors have been deposited directly into the colon of affected individuals to replace the missing normal gastrointestinal flora and suppress C. difficile toxin-producing activities.'?
Controls
While Segarra-Newnhamexpressed concern about limited information and small studies that often lack randomization, several things must be considered when evaluating probiotic studies. First, as live microorganisms, probiotics are not patentable. Therefore, few large pharmaceutical companies will engage in expensive studies, utilizing large numbers of patients in a double-blind, placebo-controlled design, because there is limited monetary incentive to do so. Such studies will always be the exception, not the norm. Second, despite the perception that probiotic studies often "lack controls," the patients in many studies actually served as their own controls. For example, when patients had up to 5 relapsesover a 2-10 month period of time with vancomycin and/or metronidazole'S" and failed to recover with "standard of care therapies" but experienced no further relapses after a short course of probiotics,the value of the probioticsin spurring their recoverycannot beignored.
Safety
While Segarra-Newnhamexpresses appropriate caution with respect to the safety of probiotics, one must be cognizant that fermented foods, containing the very same bacterial genera found in probiotics, have been used for centuries,even millennia,in the preparation of fermented vegetables and dairy products.
Lactobacilli are commensal organisms present in the oral cavity at 10 7 cfulmL, the vagina at 10 7_108 cfulg vaginal fluid, and in the gut at levels up to 10 8 cfu/g.'? While rare, Lactobacillus is recognizedas a potentialcause of endocarditis, even in the absence of probiotic supplementation. Typically, when endocarditis occurs, transient bacteremia that follows dental work, parturition,or abortion is the starting point of the infection,with the source of the organism being the patient's own normal flora. In Finland, where probiotics have been routinely added to dairy products since 1990, no change in the rate of bacteremia has been observed. There are 7 reports in the literature in which a Lactobacillus organism identified as the causative agent in an infection was identical to a probiotic strain used by the patient. Experts estimate that the risk of developing a infection from a Lactobacillus probiotic is "negligible," happening in less than 1 case per 1 million users of probioticsupplements,"
Saccharomyces boulardii, although not a commensal organism, has been used for more than 50 years in over 80 June 12,2007) . This meansthat approximately 1 person out of every 5.6 million users is at risk of developing fungemia with this probiotic; the risk is even smaller when used by otherwisehealthy persons. As virtually all cases offungemia associated with S. boulardii have involved extremely ill patients who were immunocompromised and/or had central venous catheters (believedto have been the sourceof entryfor the organism), it seems best to avoid this probiotic in similarly debilitated patients. Nonetheless, even with this risk,S. boulardii has a morefavorable safetyprofilethan nearly every prescription and over-the-counter drugon the market. It is unfortunate that Segarra-Newnham did not review bifidobacterial probiotics in her article, as most experts now recommend multiple strains of probioticbacteria for gastroenteritis, especially bifidobacteria due to its low pathogenicity and high prevalence as a commensal organism; this genera of bacteria is often used in conjunction with lactobacilli," Like lactobacillemia, bifidobactermia is extremely rare and, when reported, is usually associated with problems during pregnancy or delivery.'? Presently there are no reports of bifidobacterialsepsis occurring in conjunction with probiotic use,"
Insteadof infections, the most common adverseeffects associatedwith lactobacilli and bifidobacterial probiotics are transient flatulence and bloating. It is said that these temporary symptoms are a "die-off' effect as probiotic bacteria crowdout and eliminate pathogenic intestinal bacteria. Constipation and increased thirst have infrequently been reported withS. boulardii.
Overall,it appears that probiotics are safe for most individuals, even when compared with the host's own commensalflora. However, as probiotic supplementation does involve ingestionof live microorganisms, caution is warranted,particularly in people with central venous catheters and compromised immune systems, including transplant recipients. Probiotics have been used beneficially in prematureinfants,20·22 but discretion is advisedbecauseof immune immaturity. Theoretically, care is also warranted if probiotics are administered via jejunostomy, as there is potentialfor bacteriaor yeast from an opened probiotic capsuleor powderto enter the surgical site.
Summary
Whilethere is no doubt that prevention of C. dijficile diarrhea is the best approach through (1) judicious use of broad-spectrum antibiotics, (2) hand washing (alcohol-based gels do not eliminate spores), (3) patient isolation, and (4) thorough cleaning of affected rooms with a 10% bleach solution, probiotics are increasingly recognized as safe and effective-and sometimes necessary-adjuncts for eradicating C. difficile, particularly in individuals suffering from multiple relapses. 
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